Adamas Pharmaceuticals
ADMS
ADMS was delisted on the 23rd of November, 2021.
70 hedge funds and large institutions have $278M invested in Adamas Pharmaceuticals in 2017 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 24 increasing their positions, 22 reducing their positions, and 10 closing their positions.
9% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 22
2% more capital invested
Capital invested by funds: $273M → $278M (+$5.65M)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
10% less funds holding
Funds holding: 78 → 70 (-8)
20% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 10
64% less call options, than puts
Call options by funds: $226K | Put options by funds: $634K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$22.1M |
| 2 |
AC
Armistice Capital
New York
|
+$5.59M |
| 3 |
PVI
Pura Vida Investments
New York
|
+$4.05M |
| 4 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
+$1.7M |
| 5 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
+$1.15M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.6M |
| 2 |
NC
Nexthera Capital
New York
|
-$2.56M |
| 3 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$2.12M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.91M |
| 5 |
Millennium Management
New York
|
-$1.65M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
SG Americas Securities
New York
| – | -$143K | -8,445 | Closed |
|
77
UBS Group
Zurich,
Switzerland
| – | -$26K | -1,536 | Closed |
|
|
TRCT
78
Tower Research Capital (TRC)
New York
| – | -$18K | -1,061 | Closed |
|
79
Creative Planning
Overland Park,
Kansas
| – | -$3K | -200 | Closed |
|
80
Citigroup
New York
| – | +$17 | +1 | New |
|
ADMS Hedge Fund Activity: Q1 2017 in Review
70 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Adamas Pharmaceuticals (ADMS) for Q1 2017, worth a combined $278M — up 2.1% from $273M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of ADMS and 8 opened new positions — a net loss of 2 holders — while 22 trimmed existing stakes and 24 added.
The largest buyer was BlackRock, adding an estimated $22.1M. The largest seller was Fidelity Investments, cutting an estimated $4.6M.
- 70 institutional investors held Adamas Pharmaceuticals (ADMS) as of Q1 2017, down from 78 in Q4 2016.
- Funds reported $278M of Adamas Pharmaceuticals stock for Q1 2017, up 2.1% quarter-over-quarter.
- 8 funds opened new Adamas Pharmaceuticals positions in Q1 2017 and 10 closed out, a net change of -2 holders.
- The largest Adamas Pharmaceuticals buyer in Q1 2017 was BlackRock, an estimated $22.1M added.
- The largest Adamas Pharmaceuticals seller in Q1 2017 was Fidelity Investments, an estimated $4.6M sold.
Based on aggregated 13F filings for Q1 2017.